Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Dr. Reddy's Labs has become the world's first company to launch a generic version of Amgen's erythropoiesis-stimulating agent Aranesp (darbepoetin alfa). The biosimilar, called Cresp, has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy, Dr. Reddy's announced Aug. 9